27
https://pubmed.ncbi.nlm.nih.gov/38092979
The abstract reports on a study of eight multiple myeloma patients treated with the immunotherapy talquetamab, which found that the treatment led to rapid and significant taste changes and severe dry mouth, despite no changes in salivary flow, resulting in a significant impairment in quality of life.
